Vertex casually drops Orkambi revenue slowdown, creating

Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about | Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about the revenue slip, one analyst says.

S-1/A

SEC Filing – Royalty Pharma

SEC Filing – Royalty Pharma

March 2016 Baltimore Beacon by The Beacon Newspapers - Issuu

Vertex Pharmaceuticals' Revenue by Product (2016-2023)

Amendment No. 1 to Draft Registration Statement

Motley Fool: Smart shopping, how dumb is it to gamble and this week's trivia

SEC Filing – Royalty Pharma

Inventory Analytics: Identify And Manage Slow-Moving & Obsolete Inventory